New Purchase: Biotech Stock Whose Core Trial Drug Literally Kills People

Back in October, shares of $ALNY were decapitated after news was released that one of their core drug trial stocks killed, umm, 18 people.

Source: Forbes

The therapy, called revusiran, was being tested in patients suffering from a progressive and debilitating condition that leads to heart failure and eventually death: hereditary ATTR amyloidosis with cardiomyopathy. But trial participants started to complain of increased nerve pain and numbness, prompting the company to organize an independent committee to review trial results.

That committee concluded that “the benefit-risk profile for revusiran no longer supported continued dosing” of the drug. In fact, 18 patients died and a disproportionate share was given the actual drug, not the placebo.

Indeed.

Since then, they’ve teamed up with Sanofi, who owns a chunk of the stock, to develop a new drug — which is entering phase 3 this year. But, let’s be clear, the fundamentals are horrendous.

As for the technicals, I am not a chartist. But if I was, I’d probably tell you the stock was basing off a ‘retarded formation’ and destined for a good raping or two.

Do you know how I intend to make money in this piece of shit (Oh yeah, I forgot to mention that I just about this thing)?

Wait for it.

If you enjoy the content at iBankCoin, please follow us on Twitter